Official Title
Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Hospitalized Patients With Coronavirus Infection (COVID-19). A Randomized Trial
Brief Summary

Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Hospitalized Patients With Coronavirus Infection.

Detailed Description

Several interactions by pre-existing therapies for chronic diseases, therapies used by
SARS-CoV2 infection generate doubts about risks and benefits. Among these situations in which
the current data indicate a situation of equipoise would be about the maintenance or
suspension of ACEI / BRA in patients with SARS-CoV2 infection. Increasing the expression of
ECA-2 could increase the binding to the virus, however, there are studies that indicate this
increase in ECA-2 could be protective. So far, there is no clinical evidence to confirm any
of the theories, and this question can only be clarified through a randomized clinical trial.

The objective is to evaluate the impact of the suspension of the use of
angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (BRA) on the
length of hospital stay and on the mortality of patients with SARS-CoV2 infection.

Unknown status
Corona Virus Infection
COVID-19

Other: Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors

Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors

Eligibility Criteria

Inclusion Criteria:

- Patients hospitalized with COVID-19 diagnosis using ACE inhibitors or blockers of
angiotensin receptor;

- Patients ≥ 18 years old;

- Maximum use of 3 antihypertensive drugs;

- Sign the consent form.

Exclusion Criteria:

- Severe evolution with orotracheal intubation, use of mechanical ventilation and / or
hemodynamic instability in the first 24 hours until COVID-19 diagnosis confirmation;

- Patients hospitalized per decompensated congestive heart failure in the last 12
months;

- Use of Sacubitril/Valsartan

- Pregnancy

- Recent acute renal failure and shock

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Brazil
Locations

Idor
São Paulo, Brazil

Investigator: Renato D. Lopes, MD, PhD

Contacts

Renato D. Lopes, MD, PhD
55 11 5904 7339
renato.lopes@duke.edu

Renato D. Lopes, MD, PhD, Principal Investigator
D'Or Institute for Research and Education

Brazilian Clinical Research Institute
NCT Number
Keywords
Blockers of angiotensin receptor
Angiotensin-Converting Enzyme Inhibitors
SARS-CoV2
MeSH Terms
Infections
COVID-19
Coronavirus Infections
Enzyme Inhibitors
Angiotensin-Converting Enzyme Inhibitors
Angiotensin Receptor Antagonists